NIH panel backs delayed therapy for low-risk prostate cancer

12/12/2011 |

Treatment can be delayed for low-risk prostate cancer patients until warranted by disease progression, according to an NIH panel. Defining low-risk prostate cancer as prostate-specific antigen levels of less than 10 ng/mL and a Gleason score of 6 or less, the panel estimated that more than 100,000 men diagnosed with the cancer each year would not require immediate therapy, but only active monitoring.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC